Subcutaneous CT‐P13 and purine analogues vs intravenous CT‐P13 and purine analogues
Serious adverse events · patients with Crohn's disease (active disease population with clinical response at baseline)
The review found no eligible studies for this question.
1 finding from 1 review
- Infliximab for maintenance of medically‐induced remission in Crohn's disease 2024 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found